BACKGROUND: BRCA1 is a tumour suppressor with pleiotropic actions. Germline mutations in BRCA1 are responsible for a large proportion of breast-ovarian cancer families. Several missense variants have been identified throughout the gene but because of lack of information about their impact on the function of BRCA1, predictive testing is not always informative. Classification of missense variants into deleterious/high risk or neutral/low clinical significance is essential to identify individuals at risk. OBJECTIVE: To investigate a panel of missense variants. METHODS AND RESULTS: The panel was investigated in a comprehensive framework that included (1) a functional assay based on transcription activation; (2) segregation analysis and a method of using incomplete pedigree data to calculate the odds of causality; (3) a method based on interspecific sequence variation. It was shown that the transcriptional activation assay could be used as a test to characterise mutations in the carboxy-terminus region of BRCA1 encompassing residues 1396-1863. Thirteen missense variants (H1402Y, L1407P, H1421Y, S1512I, M1628T, M1628V, T1685I, G1706A, T1720A, A1752P, G1788V, V1809F, and W1837R) were specifically investigated. CONCLUSIONS: While individual classification schemes for BRCA1 alleles still present limitations, a combination of several methods provides a more powerful way of identifying variants that are causally linked to a high risk of breast and ovarian cancer. The framework presented here brings these variants nearer to clinical applicability.
BACKGROUND:BRCA1 is a tumour suppressor with pleiotropic actions. Germline mutations in BRCA1 are responsible for a large proportion of breast-ovarian cancer families. Several missense variants have been identified throughout the gene but because of lack of information about their impact on the function of BRCA1, predictive testing is not always informative. Classification of missense variants into deleterious/high risk or neutral/low clinical significance is essential to identify individuals at risk. OBJECTIVE: To investigate a panel of missense variants. METHODS AND RESULTS: The panel was investigated in a comprehensive framework that included (1) a functional assay based on transcription activation; (2) segregation analysis and a method of using incomplete pedigree data to calculate the odds of causality; (3) a method based on interspecific sequence variation. It was shown that the transcriptional activation assay could be used as a test to characterise mutations in the carboxy-terminus region of BRCA1 encompassing residues 1396-1863. Thirteen missense variants (H1402Y, L1407P, H1421Y, S1512I, M1628T, M1628V, T1685I, G1706A, T1720A, A1752P, G1788V, V1809F, and W1837R) were specifically investigated. CONCLUSIONS: While individual classification schemes for BRCA1 alleles still present limitations, a combination of several methods provides a more powerful way of identifying variants that are causally linked to a high risk of breast and ovarian cancer. The framework presented here brings these variants nearer to clinical applicability.
Authors: A M Dunning; M Chiano; N R Smith; J Dearden; M Gore; S Oakes; C Wilson; M Stratton; J Peto; D Easton; D Clayton; B A Ponder Journal: Hum Mol Genet Date: 1997-02 Impact factor: 6.150
Authors: Marcelo A Carvalho; Sylvia M Marsillac; Rachel Karchin; Siranoush Manoukian; Scott Grist; Ramona F Swaby; Turan P Urmenyi; Edson Rondinelli; Rosane Silva; Luis Gayol; Lisa Baumbach; Rebecca Sutphen; Jennifer L Pickard-Brzosowicz; Katherine L Nathanson; Andrej Sali; David Goldgar; Fergus J Couch; Paolo Radice; Alvaro N A Monteiro Journal: Cancer Res Date: 2007-02-15 Impact factor: 12.701
Authors: Marc Tischkowitz; Nancy Hamel; Marcelo A Carvalho; Gabriel Birrane; Aditi Soni; Erik H van Beers; Simon A Joosse; Nora Wong; David Novak; Louise A Quenneville; Scott A Grist; Petra M Nederlof; David E Goldgar; Sean V Tavtigian; Alvaro N Monteiro; John A A Ladias; William D Foulkes Journal: Eur J Hum Genet Date: 2008-02-20 Impact factor: 4.246
Authors: Vanessa C Fernandes; Volha A Golubeva; Giuliano Di Pietro; Cara Shields; Kwabena Amankwah; Thales C Nepomuceno; Giuliana de Gregoriis; Renata B V Abreu; Carly Harro; Thiago T Gomes; Ricceli F Silva; Guilherme Suarez-Kurtz; Fergus J Couch; Edwin S Iversen; Alvaro N A Monteiro; Marcelo A Carvalho Journal: J Biol Chem Date: 2019-02-14 Impact factor: 5.157
Authors: Tereza Vaclová; Nicholas T Woods; Diego Megías; Sergio Gomez-Lopez; Fernando Setién; José María García Bueno; José Antonio Macías; Alicia Barroso; Miguel Urioste; Manel Esteller; Alvaro N A Monteiro; Javier Benítez; Ana Osorio Journal: Hum Mol Genet Date: 2016-12-15 Impact factor: 6.150
Authors: Fergus J Couch; Lene Juel Rasmussen; Robert Hofstra; Alvaro N A Monteiro; Marc S Greenblatt; Niels de Wind Journal: Hum Mutat Date: 2008-11 Impact factor: 4.878
Authors: Marcelo Carvalho; Maria A Pino; Rachel Karchin; Jennifer Beddor; Martha Godinho-Netto; Rafael D Mesquita; Renato S Rodarte; Danielle C Vaz; Viviane A Monteiro; Siranoush Manoukian; Mara Colombo; Carla B Ripamonti; Richard Rosenquist; Graeme Suthers; Ake Borg; Paolo Radice; Scott A Grist; Alvaro N A Monteiro; Blase Billack Journal: Mutat Res Date: 2008-10-17 Impact factor: 2.433
Authors: Kristiina Tamboom; Krista Kaasik; Jelena Aršavskaja; Mare Tekkel; Aili Lilleorg; Peeter Padrik; Andres Metspalu; Toomas Veidebaum Journal: Hered Cancer Clin Pract Date: 2010-04-09 Impact factor: 2.857